Recent Updates — ILMN
Illumina reported third-quarter revenue of $1.13 billion, a 4.2% increase from the prior year period, driven by healthy clinical demand and robust NovaSeq X placements. GAAP diluted earnings per share were $1.43, while non-GAAP diluted EPS excluding tariff refunds was $1.44. The company raised its full-year revenue guidance to $4.64-$4.66 billion from the previous range of $4.60-$4.64 billion and increased its non-GAAP operating margin expectation to 23.6%. Illumina operates in the life sciences industry, providing DNA sequencing and array-based technologies for research, clinical, and applied markets.
On October 8, 2026, Illumina entered into definitive documentation to establish an unsecured commercial paper program with a maximum aggregate principal amount of $1.0 billion. The program allows the company to issue short-term notes maturing in up to 397 days for general corporate purposes. Three dealers were appointed to facilitate issuances, and no notes are currently outstanding under this facility. Illumina develops and sells DNA sequencing and array-based technologies.
On August 17, 2026, Illumina completed a public offering of $300 million aggregate principal amount of its 4.950% notes due September 19, 2029. The company intends to use the net proceeds from this issuance, combined with existing cash on hand, to repay $500 million in outstanding principal of its 4.650% notes maturing on September 9, 2026. This refinancing activity involves significant debt restructuring and capital management. Illumina operates in the life sciences industry, specializing in genomic sequencing technologies.
Illumina, Inc. entered into a new $1,000 million senior unsecured five-year revolving credit facility on August 13, 2026, replacing its existing agreement dated January 4, 2023. The facility includes a $50 million swingline sublimit and a $75 million letter of credit sublimit, with an option to increase commitments or add term loans up to $500 million subject to lender consent. Interest rates are variable based on the SOFR or alternate base rate plus an applicable margin tied to the company's debt rating. The facility matures on August 13, 2031, with three one-year extension options, and contains standard financial covenants including a maximum total leverage ratio. No borrowings were outstanding as of the filing date. Illumina operates in the genomics industry, providing DNA sequencing and array-based technologies for life science research and clinical diagnostics.
On August 10, 2026, Illumina entered into an underwriting agreement to issue and sell $300 million in aggregate principal amount of its 4.950% notes due 2029. The offering is expected to close on August 17, 2026, subject to customary conditions. Illumina intends to use the net proceeds from this transaction, combined with existing cash reserves, to repay its outstanding 4.650% notes maturing on September 9, 2026. This debt refinancing activity is a significant capital structure event that alters the company's near-term liability profile and interest obligations. Illumina operates in the genomics industry, providing DNA sequencing and array-based technologies for life science research and clinical diagnostics.
Illumina, Inc. filed a Form 8-K to announce the settlement and proposed dismissal of litigation captioned Icahn Partners LP, et al., v. Francis DeSouza, et al., arising from its approximately $8 billion acquisition of GRAIL, Inc. The parties entered into a Release Agreement on August 21, 2025, providing for mutual releases without any monetary payment by either side. The action will be dismissed with prejudice as to the plaintiffs only, while remaining without prejudice to other stockholders and three pending derivative actions. Defendants continue to deny all claims of wrongdoing or liability. A court hearing on the proposed dismissal is scheduled for November 2, 2026. Illumina, Inc. operates in the life sciences industry, specializing in DNA sequencing and analysis technologies.